Vericel

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 314

Market Cap: $2.6B

Website

Introduction: Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Clinical Trials

A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

Phase 3

Recruiting

Conditions: Chondral Defect
Articular Cartilage Defect
Osteochondritis Dissecans (OCD)
Articular Cartilage Disorder of Knee

Interventions: Biological: MACI
Procedure: microfracture

First Posted Date: 2018-07-17

Last Posted Date: 2024-12-02

Lead Sponsor: Vericel Corporation

Target Recruit Count: 45

Registration Number: NCT03588975

Locations: 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
Shriner's Hospital for Children Northern California, Sacramento, California, United States
🇺🇸
University of California Davis Health, Sacramento, California, United States

and more 9 locations

An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)

Phase 2

Completed

Conditions: Ischemic Dilated Cardiomyopathy (IDCM)

Interventions: Biological: ixmyelocel-T
Other: Placebo

First Posted Date: 2012-08-23

Last Posted Date: 2021-05-27

Lead Sponsor: Vericel Corporation

Target Recruit Count: 114

Registration Number: NCT01670981

Locations: 🇺🇸
UCSD Medical Center, La Jolla, California, United States
🇺🇸
Temple University, Philadelphia, Pennsylvania, United States
🇺🇸
Soltero Cardiovascular Research Center, Dallas, Texas, United States

and more 33 locations

An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)

Phase 3

Completed

Conditions: Critical Limb Ischemia

Interventions: Biological: Ixmyelocel-T
Other: Placebo

First Posted Date: 2011-12-02

Last Posted Date: 2021-05-27

Lead Sponsor: Vericel Corporation

Target Recruit Count: 41

Registration Number: NCT01483898

Locations: 🇺🇸
Union Memorial Hospital, Baltimore, Maryland, United States
🇺🇸
UCLA Gonda Venous Center & Ambulatory Procedure Unit, Los Angeles, California, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 83 locations

Extension Study for Participants of MACI00206 Study of MACI® for the Treatment of Symptomatic Articular Cartilage Defects of the Knee

Completed

Conditions: Articular Cartilage Defects

Interventions: Procedure: Microfracture
Biological: autologous cultured chondrocytes on porcine collagen membrane

First Posted Date: 2010-12-02

Last Posted Date: 2021-05-12

Lead Sponsor: Vericel Corporation

Target Recruit Count: 128

Registration Number: NCT01251588

Locations: 🇫🇷
Polyclinique Saint-Roch, Montpellier Cedex 2, France
🇳🇱
Academisch Ziekenhuis Maastricht, Maastricht, Netherlands
🇵🇱
Lekmed Medical Center, Warsow, Poland

and more 11 locations

Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy

Phase 2

Completed

Conditions: Dilated Cardiomyopathy

Interventions: Biological: Ixmyelocel-T
Other: Vehicle Control

First Posted Date: 2009-11-26

Last Posted Date: 2021-05-27

Lead Sponsor: Vericel Corporation

Target Recruit Count: 22

Registration Number: NCT01020968

Locations: 🇺🇸
Minneapolis Heart Institute, Minneapolis, Minnesota, United States
🇺🇸
University Hospitals, Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
University of Utah, Salt Lake City, Utah, United States

Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion

Phase 1

Terminated

Conditions: Single Level Posterolateral Spinal Fusion

Interventions: Biological: Bone Repair Cells (BRCs)
Procedure: Autologous bone graft

First Posted Date: 2008-11-25

Last Posted Date: 2021-05-11

Lead Sponsor: Vericel Corporation

Target Recruit Count: 2

Registration Number: NCT00797550

Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)

Phase 2

Completed

Conditions: Dilated Cardiomyopathy

Interventions: Other: Standard of Care
Biological: Ixmyelocel-T

First Posted Date: 2008-10-03

Last Posted Date: 2021-05-27

Lead Sponsor: Vericel Corporation

Target Recruit Count: 40

Registration Number: NCT00765518

Locations: 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇺🇸
The University of Utah School of Medicine, Salt Lake City, Utah, United States

and more 2 locations

Superiority of MACI® Versus Microfracture Treatment in Patients With Symptomatic Articular Cartilage Defects in the Knee

Phase 3

Completed

Conditions: Articular Cartilage Defect

Interventions: Biological: autologous cultured chondrocytes on porcine collagen membrane
Procedure: Microfracture

First Posted Date: 2008-07-21

Last Posted Date: 2021-05-12

Lead Sponsor: Vericel Corporation

Target Recruit Count: 144

Registration Number: NCT00719576

Locations: 🇵🇱
Center for Sports Medicine CMS, Warsaw, Poland
🇳🇱
St. Elisabeth Ziekenhuis, Tilburg, Netherlands
🇵🇱
Szpital Uniwersytecki, Bydgoszcz, Poland

and more 17 locations

Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head

Phase 3

Completed

Conditions: Osteonecrosis

Interventions: Biological: Ixmyelocel-T
Other: Standard of Care Only

First Posted Date: 2007-07-23

Last Posted Date: 2019-10-21

Lead Sponsor: Vericel Corporation

Target Recruit Count: 11

Registration Number: NCT00505219

Locations: 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸
Lutheran Medical Center, Brooklyn, New York, United States
🇺🇸
University of Minnesota Department of Orthopaedic Surgery, Minneapolis, Minnesota, United States

Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia

Phase 2

Completed

Conditions: Peripheral Arterial Disease

Interventions: Biological: Placebo
Biological: Ixmyelocel-T

First Posted Date: 2007-05-01

Last Posted Date: 2020-05-20

Lead Sponsor: Vericel Corporation

Target Recruit Count: 86

Registration Number: NCT00468000

Locations: 🇺🇸
University of North Carolina Hospitals, Chapel Hill, North Carolina, United States
🇺🇸
Jobst Vascular Center, Toledo, Ohio, United States
🇺🇸
Scott and White Hospital, Temple, Texas, United States

and more 17 locations

Home Terms & Conditions Privacy Policy